

## Novel Approaches in the Management of Hepatocellular Carcinoma: From Surveillance to Treatment

Guest Editors:

**Dr. Gian Paolo Caviglia**

Department of Medical Sciences,  
University of Turin, I-10126 Turin,  
Italy

**Dr. Silvia Gaia**

Unit of Gastroenterology, AOU  
Città della Salute e della Scienza  
– Molinette Hospital, 10126 Turin,  
Italy

Deadline for manuscript  
submissions:

**closed (31 May 2022)**

### Message from the Guest Editors

Dear Colleagues,

Liver cancer is the sixth most common cancer in terms of incidence and the third in terms of mortality worldwide, with approximately 841,000 new cases and 782,000 deaths per year; hepatocellular carcinoma (HCC) represents more than 90% of primary liver cancers. Chronic inflammation that characterizes the natural history of chronic hepatitis leads to fibrosis progression, and, overtime, to cirrhosis, a pre-neoplastic condition at high risk for HCC development. Additionally, the molecular alterations that underlie cirrhosis and dysplastic lesions provide dysplastic cells with proliferative, invasive, and survival advantages moving toward the onset of HCC. It is estimated that one-third of patients with cirrhosis will develop HCC during their lifetime.

